M

Merck

Makes medicines, vaccines and animal treatments

Regional Medical Scientific Director - Immunology

Full-TimeUpdated on 10/23/2026Deadline 10/27/26
$190.8k - $300.3k+ Annual bonus + Long-term incentive
Mid
Bachelor's, PharmD, PhD, MD
Remote in USA
RemoteCandidates must reside within the Southern-Midwest territory.
Biology & Biotech
No H1B Sponsorship

About the job

Requirements
  • The required education is a PhD, PharmD, DNP, DO, or MD.
  • Proven competence and three years of relevant Immunology (Inflammatory Bowel Disease) experience beyond that obtained in the terminal degree program.
  • Ability to conduct doctoral-level discussions with key external stakeholders.
  • Thorough comprehension of FDA, OIG, HIPAA, and other ethical guidelines, laws, and regulations relevant to the pharmaceutical industry and its customers.
  • Strong working knowledge of Microsoft Office Suite, including Word, PowerPoint, Excel, Teams, and OneNote.
  • Familiarity with virtual meeting platforms.
  • Candidates must reside within the Southern-Midwest territory.
  • Ability to travel up to 50% within the territory.
  • A valid driving license is required.
Responsibilities
  • Develop professional relationships and engage with national and regional Scientific Leaders to ensure access to company-approved medical and scientific information on areas of therapeutic interest and company products.
  • Conduct peer-to-peer scientific discussions and maintain a reliable presence with Scientific Leaders so they have a medical contact within the company.
  • Address scientific questions and direct inquiries outside the role's scope, such as grants, to appropriate company resources consistent with applicable policies.
  • Maintain current knowledge and comprehension of the dynamic scientific and clinical environment in the company's areas of interest for the assigned therapeutic area.
  • Upon request from the Global Center for Scientific Affairs, initiate discussions with Scientific Leaders and potential investigators involving scientific and data exchange in the areas of interest to assess alignment with research strategies, study concepts, scientific merit, and qualifications for a specific compound or trial.
  • Enhance understanding of the scientific foundations and goals of investigator-sponsored research.
  • Identify barriers to patient enrollment and retention to help achieve study milestones.
  • Upon request from Global Clinical Trial Operations, recommend study sites and identify potential investigators for phase II–IV clinical development programs, conduct Site Initiation Visits, and detect barriers to patient enrollment and retention.
  • Collaborate with Global Clinical Trial Operations on protocol lead responsibilities.
  • Address investigators' questions and provide information about participation in company-sponsored clinical studies.
  • Engage in scientific congresses and medical meetings and facilitate scientific and data exchange concerning both company and competitor data.
  • Gather feedback, data, and information during routine activities to help the company understand the medical or scientific needs, priorities, and concerns of Scientific Leaders and patients.
  • Work independently and as a team member with integrity, precision, accomplishment, motivational ambition, respect, and inclusion.
  • Serve as a role model for creating, leading, and retaining an inclusive workforce and contribute to an environment of belonging, inclusion, engagement, and empowerment.
  • Contribute to transforming the environment, culture, and business landscape; leverage inclusion to support business value in line with the global inclusion strategy; drive accountability for an inclusive culture; and strengthen foundational elements of inclusion.
  • Adhere consistently to field and corporate policies and Global Medical Scientific Affairs strategy, including field standard operating procedures, Good Clinical Practice guidelines, and administrative and operational responsibilities.
  • Serve as a role model for other field medical team members through onboarding and sharing therapeutic expertise.
Desired Qualifications
  • Additional experience in Immunology, Rheumatology, and/or Dermatology.
  • Field-based medical experience.
  • Research experience.
  • A demonstrated record of scientific or medical publication.

About the company

Merck develops prescription medicines, vaccines and veterinary treatments for patients, health systems and animal owners worldwide. Its vaccine portfolio includes Gardasil 9, which helps prevent cancers and other diseases caused by several types of human papillomavirus. The company takes potential treatments through laboratory research and clinical trials, then manufactures and sells approved products to drug distributors, hospitals, physicians and governments. Its animal health division sells medicines and vaccines to veterinarians, farmers and pet owners, while selected drug partnerships also earn shared profits or royalties. Founded in 1891, Merck is headquartered in Rahway, New Jersey.

Company Size

10,001+

Company Stage

IPO

Headquarters

Rahway, New Jersey

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • U.S. employees build retirement benefits: Merck pairs a defined benefit pension with a matching 401(k).
  • Scientists work within a large research network: Merck reports approximately 24,700 employees in R&D.
  • Animal health adds growth: August 2026 results report Q2 sales of $1.8 billion, up 8% year over year.

What critics are saying

  • Job security faces cuts: Merck's active restructuring program eliminates roles and shrinks its global real estate footprint.
  • Keytruda protection narrows: its main U.S. patent expires in 2028, with additional patents expiring in 2029.
  • Revenue is concentrated: August 2026 results show Keytruda products generated $8.4 billion of Merck's $16.6 billion Q2 sales.

What makes Merck unique

  • Merck extends into farm technology: SenseHub continuously monitors livestock for behavioral and physiological changes.
  • Merck publishes open medical knowledge: its Manuals give clinicians and patients free online references.
  • Merck's donation commitment is open-ended: Mectizan supplies for river blindness continue for as long as needed.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

-19%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Oct 22nd, 2026
Moderna sinks 18% after leak of melanoma vaccine data showing 42% lower recurrence risk

Moderna shares fell 18% after detailed Phase 3 results for its personalised melanoma vaccine, developed with Merck, appeared online two days before their scheduled presentation. The data surfaced on medical news site Oncology Central and was taken down shortly afterwards. Trading in Moderna was halted for volatility. The leaked data still looks positive. Adding the vaccine, intismeran autogene, to Merck's Keytruda cut the risk of recurrence or death by 42% versus Keytruda alone. After two years, 82.2% of patients on the combination were alive and cancer-free, against 70% on Keytruda alone. The trial enrolled 1,137 patients. The stock had risen more than eightfold this year, and traded at about 52x forward sales before the drop. The 42% figure also trails the 49% from the smaller Phase 2b trial. Full results are due at the ESMO Congress on Saturday.

Yahoo Finance
Oct 22nd, 2026
Pfizer's 5.7% yield signals risk: dividends took 108% of free cash flow vs Merck's 66%

Merck's dividend looks safer than Pfizer's, despite Pfizer's higher yield, according to a 24/7 Wall St. comparison. Pfizer yields about 5.7% against Merck's 2.2%. In 2025, Pfizer's dividends used 108% of free cash flow, while Merck's used 66%. In the first half of 2026, Merck's free cash flow covered 174% of its payout; Pfizer's covered about 51%. Merck has raised its quarterly dividend 39% since 2020, to $0.85. Pfizer's rose 13% and has been flat at $0.43 since January 2025. Pfizer is cheaper, at about 10 times 2026 earnings against Merck's 17. Pfizer targets a return to growth from 2029, while Merck's newer drugs are already selling.

Yahoo Finance
Oct 21st, 2026
Keytruda is half of Merck's $16.6B quarterly sales, so what if growth stalls?

Merck's Keytruda cancer drug family generated $8.4 billion in fiscal Q2 2026, about half of the company's $16.6 billion revenue. Excluding currency, Keytruda sales grew 4%, the same pace as total revenue. Management said on the August 4 call that US Keytruda growth will moderate as the drug reaches peak penetration. A Dutch court has also barred Merck from selling subcutaneous Keytruda in eight European markets, Barron's reported. Newer drugs are growing faster. WINREVAIR sales rose 75% to $588 million, and WELIREG sales rose 67%. Free cash flow of $16.1 billion covered dividends of $8.3 billion about twice. Total debt rose to $53.9 billion from $35.4 billion a year earlier. Merck is expected to report results on October 29.

Citybiz
Oct 20th, 2026
Epicrispr Biotechnologies appoints Enoch Kariuki to Board of Directors.

Epicrispr Biotechnologies appoints Enoch Kariuki to Board of Directors. October 20, 2026 Enoch Kariuki Epicrispr Biotechnologies, a clinical-stage biotechnology company developing epigenetic therapies, has appointed Enoch Kariuki, PharmD, to its Board of Directors as the company advances its lead treatment candidate, EPI-321, toward pivotal clinical development and expands its pipeline of gene-modulating medicines. Kariuki brings extensive experience in biotechnology operations, corporate strategy, capital markets and business development. Throughout his career, he has participated in more than $10 billion in strategic financings and mergers and acquisitions across the life sciences industry. His appointment strengthens Epicrispr's board as the company works to advance its clinical programs, evaluate development priorities and establish the financial and operational infrastructure needed to support future growth. "Enoch is an accomplished biotechnology leader with a proven track record of building and scaling companies, guiding programs through pivotal clinical and regulatory milestones, and executing strategic transactions that create lasting value," said Amber Salzman, Ph.D., CEO of Epicrispr Biotechnologies. Salzman said Kariuki's combination of operational, financial and strategic experience will support the company's efforts to advance EPI-321 and develop additional epigenetic medicines. Kariuki currently serves as President of Endeavor BioMedicines, where he oversees corporate strategy and operations. His responsibilities include guiding organizational development and supporting the company's business and clinical development objectives. Previously, he served as CEO of Lengo Therapeutics, a biotechnology company acquired by Blueprint Medicines. He also held the position of Chief Financial Officer at VelosBio, which was acquired by Merck. Earlier in his career, Kariuki was Senior Vice President of Corporate Development at Synthorx, where he led the company's initial public offering and played a significant role in its subsequent acquisition by Sanofi. His experience also includes investment and advisory positions at H.I.G. Capital, Leerink Partners and UBS Investment Bank, providing a background in financing, strategic transactions and biotechnology investment analysis. These roles have given Kariuki experience across multiple stages of biotechnology company development, from securing financing and establishing corporate strategy to executing acquisitions and supporting clinical-stage growth. At Epicrispr, that experience will be relevant as the company evaluates the resources, partnerships and development strategies required to advance its therapeutic programs. Epicrispr's lead candidate, EPI-321, is being evaluated in clinical trials for facioscapulohumeral muscular dystrophy (FSHD), a genetic neuromuscular disease characterized by progressive muscle weakness. The company is developing EPI-321 using its proprietary Gene Expression Modulation System (GEMS), an epigenetic technology platform designed to regulate gene expression without directly changing the underlying DNA sequence. Epigenetic therapies seek to influence how genes are activated or suppressed. Epicrispr's approach is intended to provide precise and durable modulation of gene activity, potentially addressing diseases associated with abnormal gene expression. The company is initially concentrating on neuromuscular disorders while developing additional gene-modulating treatments for other conditions. Advancing EPI-321 toward pivotal development represents an important operational priority. Clinical-stage biotechnology companies approaching later-stage trials must address study design, regulatory engagement, manufacturing readiness, financing requirements and long-term commercialization planning. Board members with experience in clinical development and capital markets can provide oversight as management evaluates those requirements and determines how to allocate resources across its pipeline. "Epicrispr is at an exciting inflection point, with compelling early clinical data supporting the potential of its differentiated epigenetic platform to address diseases with significant unmet medical needs," Kariuki said. He identified EPI-321's development in FSHD and the company's broader epigenetic technology platform as areas of opportunity, while emphasizing his intention to support Epicrispr's strategic priorities. In addition to his executive responsibilities, Kariuki serves on the boards of Zentalis Pharmaceuticals and Pheon Therapeutics, chairing the audit committees at both companies. He previously served on the boards of Imago Biosciences and ProfoundBio, which were acquired by Merck and Genmab, respectively. His board experience includes financial oversight and corporate governance responsibilities relevant to biotechnology companies operating in capital-intensive research and development environments. Kariuki earned a Doctor of Pharmacy degree from Texas Southern University and an MBA from the Tuck School of Business at Dartmouth College. He also completed a postdoctoral fellowship in research and development strategy and analytics at Bristol Myers Squibb. Epicrispr continues to advance EPI-321 through clinical development while expanding its portfolio of gene-modulating therapies. Kariuki's appointment adds biotechnology financing, transaction and operational experience to the board as the company prepares for its next stage of clinical development and evaluates opportunities to advance its epigenetic medicines platform.

Ash
Oct 20th, 2026
Ash announces $10M Series A funding to uplevel at-home health testing to close healthcare gaps for millions

Ash secures $10M Series A funding led by Merck GHI Fund. We are scaling at home lab test programs to close care gaps and bring patients into the care cycle.